试验注册
评估丙磺舒对健康受试者中米达美替尼及其代谢物药代动力学影响的研究
A Study to Assess the Effects of Probenecid on the Pharmacokinetics of Mirdametinib and Its Metabolites in Healthy Participants
作者：Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
ClinicalTrials.gov · 2026年9月25日 · Merck Healthcare KGaA, Darmstadt, Germa…
不需要生物学背景，多打比方
正在获取全文并生成讲解（拿不到全文就依据摘要）…
已等待 0 秒大约需要 10–20 秒
可以先看别的，做好了会自动出现在这里。
这篇还没有动画
动画会把研究的流程、作用机制和关键结果一步一步演示出来，每一步都标明出自原文哪里。制作大约需要一两分钟。
摘要Abstract
Brief summary: This is a single-centre, open-label, fixed-sequence, 2-period study in healthy participants. The total study duration for each participant will be up to approximately 56 days, including a 28-day screening period, a 19-day assessment period (including Period 1 and Period 2), and a follow-up (FU) visit approximately 7 days after clinical research unit (CRU) discharge.
Conditions: Healthy
Interventions: drug: Mirdametinib; drug: Probenecid
Phase: Phase 1
Enrollment: 17 (estimated)
Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (industry)
Countries: Germany
Status: not yet recruiting
还没有查过关联研究
我会去找这篇研究之前的基础工作、做类似事情的研究，以及之后引用它的研究，并说明每篇为什么相关。